• Something wrong with this record ?

Therapy of chronic hepatitis C in people who inject drugs: focus on adherence

S. Frankova, Z. Jandova, G. Jinochova, M. Kreidlova, D. Merta, J. Sperl

. 2021 ; 18 (1) : 69. [pub] 20210630

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22004171

BACKGROUND: Intravenous drug use (IVDU) represents the major factor of HCV transmission, but the treatment uptake among people who inject drugs (PWID) remains low owing to a false presumption of low efficacy. The aim of our study was to assess treatment efficacy in PWID and factors determining adherence to therapy. METHODS: A total of 278 consecutive patients starting DAA (direct-acting antivirals) therapy were included, divided into two groups: individuals with a history of IVDU, PWID group (N = 101) and the control group (N = 177) without a history of IVDU. RESULTS: Sustained virological response 12 weeks after the end of therapy (SVR12) was achieved by 99/101 (98%) and 172/177 (98%) patients in the PWID and control group, respectively; in PWID group, two patients were lost to follow-up, and in the control group, four patients relapsed and one was lost to follow-up. PWID patients postponed appointments significantly more often, 29 (28.7%) in PWID versus 7 (4%) in the control group, p = 0.001. Thirteen of 101 (12.9%) and six of 177 (3.4%) patients in the PWID and in the control group, respectively, missed at least one visit (p < 0.01). However, postponing visits led to a lack of medication in only one PWID. In the PWID group, older age (p < 0.05; OR 1.07, 95% CI 1.00-1.20) and stable housing (p < 0.01; OR 9.70, 95% CI 2.10-56.20) were factors positively contributing to adherence. Contrarily, a stable job was a factor negatively influencing adherence (p < 0.05; OR 0.24, 95% CI 0.06-0.81). In the control group, none of the analyzed social and demographic factors had an impact on adherence to therapy. CONCLUSIONS: In PWID, treatment efficacy was excellent and was comparable with SVR of the control group. Stable housing and older age contributed to a better adherence to therapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004171
003      
CZ-PrNML
005      
20250402154145.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12954-021-00519-y $2 doi
035    __
$a (PubMed)34193156
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Fraňková, Soňa $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 14021, Prague, Czech Republic. sona.frankova@ikem.cz $7 xx0329475
245    10
$a Therapy of chronic hepatitis C in people who inject drugs: focus on adherence / $c S. Frankova, Z. Jandova, G. Jinochova, M. Kreidlova, D. Merta, J. Sperl
520    9_
$a BACKGROUND: Intravenous drug use (IVDU) represents the major factor of HCV transmission, but the treatment uptake among people who inject drugs (PWID) remains low owing to a false presumption of low efficacy. The aim of our study was to assess treatment efficacy in PWID and factors determining adherence to therapy. METHODS: A total of 278 consecutive patients starting DAA (direct-acting antivirals) therapy were included, divided into two groups: individuals with a history of IVDU, PWID group (N = 101) and the control group (N = 177) without a history of IVDU. RESULTS: Sustained virological response 12 weeks after the end of therapy (SVR12) was achieved by 99/101 (98%) and 172/177 (98%) patients in the PWID and control group, respectively; in PWID group, two patients were lost to follow-up, and in the control group, four patients relapsed and one was lost to follow-up. PWID patients postponed appointments significantly more often, 29 (28.7%) in PWID versus 7 (4%) in the control group, p = 0.001. Thirteen of 101 (12.9%) and six of 177 (3.4%) patients in the PWID and in the control group, respectively, missed at least one visit (p < 0.01). However, postponing visits led to a lack of medication in only one PWID. In the PWID group, older age (p < 0.05; OR 1.07, 95% CI 1.00-1.20) and stable housing (p < 0.01; OR 9.70, 95% CI 2.10-56.20) were factors positively contributing to adherence. Contrarily, a stable job was a factor negatively influencing adherence (p < 0.05; OR 0.24, 95% CI 0.06-0.81). In the control group, none of the analyzed social and demographic factors had an impact on adherence to therapy. CONCLUSIONS: In PWID, treatment efficacy was excellent and was comparable with SVR of the control group. Stable housing and older age contributed to a better adherence to therapy.
650    _2
$a senioři $7 D000368
650    _2
$a antivirové látky $x terapeutické užití $7 D000998
650    12
$a hepatitida C $x farmakoterapie $7 D006526
650    12
$a chronická hepatitida C $x komplikace $x farmakoterapie $7 D019698
650    _2
$a lidé $7 D006801
650    12
$a léčivé přípravky $7 D004364
650    12
$a intravenózní abúzus drog $x komplikace $x farmakoterapie $7 D015819
650    _2
$a setrvalá virologická odpověď $7 D000072230
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jandova, Zuzana $u Psychiatric Hospital Havlickuv Brod, Havlickuv Brod, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Jinochova, Gabriela $u Psychiatric Hospital Havlickuv Brod, Havlickuv Brod, Czech Republic $u Addiction Centre Prague, Prague, Czech Republic
700    1_
$a Kreidlova, Miluse $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Merta, Dusan $u Cardiothoracic Anaesthesiology and Intensive Care, Department of Anaesthesiology and Intensive Care Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Sperl, Jan $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 14021, Prague, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00175640 $t Harm reduction journal $x 1477-7517 $g Roč. 18, č. 1 (2021), s. 69
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34193156 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20250402154141 $b ABA008
999    __
$a ok $b bmc $g 1751587 $s 1155320
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 18 $c 1 $d 69 $e 20210630 $i 1477-7517 $m Harm reduction journal $n Harm Reduct J $x MED00175640
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Archiving options